Assenagon Asset Management S.A. Buys 100,740 Shares of Insulet Corporation $PODD

Assenagon Asset Management S.A. boosted its position in shares of Insulet Corporation (NASDAQ:PODD) by 64.2% in the first quarter, Holdings Channel reports. The fund owned 257,719 shares of the medical instruments supplier’s stock after purchasing an additional 100,740 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Insulet were worth $54,080,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in the business. NewEdge Advisors LLC lifted its stake in shares of Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 64 shares in the last quarter. Cresset Asset Management LLC grew its stake in shares of Insulet by 7.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock worth $813,000 after buying an additional 177 shares in the last quarter. Cerity Partners LLC grew its position in Insulet by 68.7% in the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock worth $5,423,000 after acquiring an additional 7,030 shares in the last quarter. Sei Investments Co. increased its position in shares of Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after purchasing an additional 29,584 shares during the last quarter. Finally, Treasurer of the State of North Carolina increased its position in Insulet by 2.5% during the second quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after acquiring an additional 791 shares during the last quarter.

Insiders Place Their Bets

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.36% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. UBS Group set a $219.00 price target on Insulet in a report on Thursday, June 11th. Robert W. Baird lowered their price target on shares of Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 price objective (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Piper Sandler cut their price target on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Finally, Jefferies Financial Group dropped their price target on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $238.67.

Insulet Stock Up 3.3%

Insulet stock opened at $153.82 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The business has a 50 day simple moving average of $159.98 and a 200-day simple moving average of $221.08. The stock has a market capitalization of $10.65 billion, a PE ratio of 35.77, a price-to-earnings-growth ratio of 1.17 and a beta of 1.13. Insulet Corporation has a 12 month low of $138.79 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same period last year, the firm posted $1.02 earnings per share. The company’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts anticipate that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.